Xencor Receives Milestone Payment from Merck for Initiation of Phase 1 ... MarketWatch MONROVIA, Calif., April 10, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR) , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and ... Xencor Reports Fourth Quarter and Full Year 2013 Financial Results Xencor Gets Milestone Payment From Merck |
